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Abstract
The design of bioactive three-dimensional (3D) scaffolds is a major focus in bone tissue engineering. Incorporation of
growth factors into bioprinted scaffolds offers many new possibilities regarding both biological and architectural properties
of the scaffolds. This study investigates whether the sustained release of bone morphogenetic protein 2 (BMP-2) influences
osteogenicity of tissue engineered bioprinted constructs. BMP-2 loaded on gelatin microparticles (GMPs) was used as a
sustained release system, which was dispersed in hydrogel-based constructs and compared to direct inclusion of BMP-2 in
alginate or control GMPs. The constructs were supplemented with goat multipotent stromal cells (gMSCs) and biphasic
calcium phosphate to study osteogenic differentiation and bone formation respectively. BMP-2 release kinetics and
bioactivity showed continuous release for three weeks coinciding with osteogenicity. Osteogenic differentiation and bone
formation of bioprinted GMP containing constructs were investigated after subcutaneous implantation in mice or rats. BMP-
2 significantly increased bone formation, which was not influenced by the release timing. We showed that 3D printing of
controlled release particles is feasible and that the released BMP-2 directs osteogenic differentiation in vitro and in vivo.
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Introduction
For the treatment of large bone defects currently auto- or
allograft bone grafts are being used. Both graft types have
drawbacks such as limited availability of donor tissue, donor site
morbidity (autograft) or inferior performance (allograft) [1,2].
Tissue engineered bone constructs could ideally reduce the need
for donor bone; this is an important pillar in the field of
regenerative medicine. Within these constructs signaling molecules
such as growth factors are used to induce cellular growth,
proliferation and differentiation [3,4].
BMP-2 is a potent osteoinductive growth factor (both in vitro and
in vivo) that belongs to the transforming growth factor-b (TGF-b)
protein superfamily. BMP-2 stimulates MSCs towards osteogenic
differentiation [5] and has been used in the clinic for spinal fusion
surgery and tibial fracture healing [6]. Protein delivery via a
collagen sponge results in a BMP-2 presence of up to 8 days locally
[7], resulting from a half-life of only 7–16 minutes systemically,
due to fast degradation by proteinases [8]. Studies have shown that
BMP-2 containing products that are used in the clinic release the
protein with a large initial burst [9]. The dosage used in these
clinical applications is much higher than the effective dose in order
to compensate for the fast wash-out of the protein. The use of
BMP-2 in spinal fusion is associated with an increased risk of bone
overgrowth, problems due to exposed dura/nerves and osteolysis.
An increased risk of malignancies is suspected for products
applying the highest concentration [6,10]. In uncomplicated
fracture healing, the gene coding for BMP-2 is upregulated for
about four weeks after fracture, which supports the approach to
strive for a more sustained release of the BMP-2 protein at lower
dosage, as an alternative and effective strategy in enhancing
osteogenic differentiation and bone formation while reducing the
risk of side effects and complications [11–13]. To accomplish such
a gradual and sustained release many controlled release vehicles
have been described in literature; gelatin microparticles (GMPs)
are particularly promising because growth factors can be
incorporated into these microspheres by simple post-loading,
thereby avoiding chemical reactions that can damage the activity
of fragile proteins such as BMP-2. The post-loading strategy is
facilitated by the formation of polyion complexes between charged
amino acid residues present in both growth factors and gelatin
macromolecules. In addition, GMPs are non-cytotoxic, biode-
gradable and have already been used in numerous formulations as
isolated particles or incorporated as dispersed phase into hydrogels
to deliver BMP-2 and other growth factors such as TGF-b1 and
bFGF [14,15].
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The performance of hydrogels as scaffold materials can be
improved by introducing porosity, which lowers the diffusion
distance of oxygen and other nutrients to the center of the
construct [16]. By applying the bioprinting technology, porosity of
hydrogel-based constructs is easily achieved. In addition, the
technique of 3D fiber deposition enables production of scaffolds
with a defined architecture and regional differences by computer
controlled deposition of the cell- and growth factor laden hydrogel
[17]. A well-known hydrogel is alginate, an non-toxic biocompat-
ible anionic polysaccharide polymer, which gelates by addition of
divalent cations such as Ca2+, forming reversible ionic bridges
between the polymer chains [18]. Alginate is very suitable as a
material for 3D printing because it is a viscous, cell-friendly and
rapidly crosslinkable hydrogel in which bone formation has been
previously reported [19–21].
The present study combined controlled growth factor release
with bioprinting technology to enable production of hydrogel
scaffolds with properties that can be tuned both in time and space.
This study describes bioprinting of hydrogel scaffolds in which
controlled release particles containing BMP-2 are included. We
investigated whether prolonged BMP-2 presence in scaffolds
promotes osteogenic differentiation and bone formation compared
to fast growth factor release. Osteogenic differentiation and bone
formation in the composite hydrogel scaffolds were observed in
vitro and in vivo, respectively.
Materials and Methods
Experimental design
Three experimental groups are investigated in consecutive
experimental settings throughout the paper, namely: 1. Control
group with empty gelatin microparticles (GMPs) (i.e. PBS-laden),
2. Fast release group with empty GMPs and BMP-2 added directly
to the hydrogel, 3. Slow release group with BMP-2-loaded GMPs,
dispersed in the hydrogel (Table 1). BMP-2 concentrations were
adjusted to the calculated effective dose per experimental setup,
based on literature [22–24].
In vitro we investigated release kinetics and bioactivity of BMP-2
from GMPs. Osteogenic differentiation was monitored in
bioprinted, cell-laden alginate constructs in vitro and in vivo, after
subcutaneous implantation in mice, using flow cytometry and
immunohistochemistry. All investigative groups were subsequently
combined with ceramic cylinders and implanted subcutaneously in
rats to study bone formation using histomorphometry.
Production of gelatin microparticles (GMPs)
We adapted the protocol previously described by Tabata et al.
[25,26]. A water in oil emulsion was made using water dissolved
gelatin type B (Sigma, St Louis, MO, USA) 10% (w/v) that was
added drop wise to refined olive oil (Arcos Organics, NJ, USA) at
60u Celsius. The solution was stirred (350 rpm) for 15 minutes and
then rapidly cooled with an ice bath to induce gelation of gelatin
droplets. The microparticles were washed with 150 ml of chilled
acetone and filtered under pressure (filter paper grade 2,
Whatman, Tokyo, Japan). The microparticles were sieved and
covalently cross-linked overnight using a 10.6 mM aqueous
glutaraldehyde solution (Merck, Darmstadt, Germany) [27,28].
Three washing steps with 100 mM glycine solution (Sigma, St
Louis, MO, USA) were applied to remove residual aldehyde
groups. Subsequently, the microparticles were washed in deion-
ized water (MilliQ) three times, freeze-dried overnight and kept at
4uC in a vacuum container until use. The microparticles were
loaded with the dissolved growth factor by diffusional loading.
Radiolabeling of BMP-2
Human recombinant BMP-2 (InductOS, Wyeth/Pfizer, New
York, NY, USA) was labeled with 125I according to the iodogen
method [29]. Seventy-five ml of a 0.337 mg/ml BMP-2 solution
was pipetted into a 100 mg iodogen coated tube containing 10 ml
125I (radioactivity = 1000 mCi, Perkin-Elmer, Boston, MA, USA).
A 0.5 M phosphate buffer solution with a pH of 7.0 was added to
a total volume of 100 ml. This was incubated for 10 minutes at
room temperature, then 100 ml of saturated tyrosine solution in
PBS was added to react with unbound 125I in the solution. The
reaction mixture was filtered over Sephadex G25M column (PD-
10, Pharmacia, Uppsala, Sweden) and eluted with 1 mM NaCl
with 0.5% BSA (pH 7.0). The fraction with the highest
radioactivity was used for the release study. The resulting 125I-
BMP-2 solution was diluted to a concentration of 12 mg/ml for
further use.
In vitro release of BMP-2 measured by radiolabeling
Microspheres were loaded with 125I-BMP-2 by diffusional
loading. 25 ml of a 12 mg/ml 125I-BMP-2 solution was placed on
5 mg microspheres (n = 4) and kept at 4u Celsius overnight to
allow complete growth factor absorption. These samples, each
containing 300 ng 125I-BMP-2, were put in PBS with 400 ng/ml
bacterial collagenase type 1A (Sigma, St Louis, MO, USA) and
0.001 % (w/v) sodium azide (Wako, Kyoto, Japan) as the release
medium. The release medium was refreshed at multiple time
Table 1. Experimental groups.
Model Group GMPs [BMP-2] Method Hydrogel Ceramic Cells
In vitro 1. Control PBS laden None Bioprinted Alginate None gMSCs
2. Fast PBS laden 25 ng/ml
3. Slow BMP-2 laden 25 ng/ml
Mouse 1. Control PBS laden None Bioprinted Alginate Granules gMSCs
2. Fast PBS laden 250 ng/ml 106–212 mm
3. Slow BMP-2 laden 250 ng/ml
Rat 1. Control PBS laden None Cast Matrigel Cylinder None
2. Fast PBS laden 100 mg/ml 7 mm
3. Slow BMP-2 laden 100 mg/ml 3 mm height
doi:10.1371/journal.pone.0072610.t001
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points after centrifuging for 5 minutes at 10,000 rpm to spin down
the particles. Release was determined by measuring the residual c-
irradiation in the supernatant using a shielded c-counter (Wizard,
Pharmacia-LKB, Uppsala, Sweden) and corrected for radioactive
decay.
In vitro release of BMP-2 measured by ELISA
Microspheres (25 mg) were loaded with 10 mg/ml BMP-2 in
PBS/0.5 % BSA by diffusional loading overnight at 4uC. Samples
were placed into the top compartments of a Transwell system
(0.4 mm pores, Corning Sigma, St Louis, MO, USA). The release
medium (PBS/0.5 % BSA) in the lower compartment was
refreshed at multiple time points. Release was determined by
measuring the amount of BMP-2 in the release medium samples in
duplicate by ELISA (R&D, Minneapolis, MN, USA). Data are
expressed as cumulative release in % of total input.
Cell culture
gMSCs were obtained from bone marrow aspiration from iliac
wings of adult Dutch milk goats (n = 3). This procedure was
performed with permission of the local Ethical Committee for
Animal Experimentation in compliance with the Institutional
Guidelines on the use of laboratory animals. MSCs were isolated
by their adherence to plastic tissue culture flasks. They were
cultured in expansion medium, consisting of alpha minimum
essential medium (a-MEM, Gibco, Breda, The Netherlands) that
was supplemented with 15 % (v/v) fetal calf serum (Cambrex),
100 U/ml penicillin with 100 mg/ml streptomycin (Gibco), and
2 mM L-glutamine (Glutamax, Gibco). All cells were cultured in a
humidified incubator at 37uC and 5 % CO2.
Hydrogel preparation
Alginate powder (IMCD, Amersfoort, the Netherlands) was
sterilized by UV-radiation and dissolved at a concentration of
30 mg/ml in a-MEM (Gibco) supplemented with 25 mM CaCl2.
This prepolymerised alginate has a suitable viscosity for 3D-
printing. gMSCs were added to the gel in a concentration of
107 cells/ml, and for the in vivo scaffolds 5% (w/v) biphasic
calcium phosphate granules (BCP-1150 containing 82 % HA and
18 %TCP, Xpand, Bilhoven, the Netherlands) with a diameter of
106–212 mm were added to improve scaffold osteoconductivity.
Matrigel (growth factor reduced, BD, New Jersey, USA) was
thawed overnight at 4 uC.
Bioprinting
The Bioscaffolder pneumatic dispensing systems (SYS+ENG,
Gladbeck, Germany) was used for bioprinting of the hydrogel
scaffolds [17]. Blocks of 2062063 mm with vertically connected
pores were designed with CAD/CAM software and translated to
the NC-code for layer by layer material deposition (Figure 1).
Scaffolds were printed in a laminar flow-cabinet into tissue culture
plates. After printing, the scaffolds were crosslinked by adding
100 mM CaCl2 dissolved in MilliQ. After 15 minutes, the CaCl2
solution was removed, the constructs washed with Tris buffered
saline (TBS) and cultured in 5 ml culture medium. Directly after
printing one sample of each group was processed for paraffin
embedding and stained with hematoxylin and eosin to assess the
distribution of the different components within the constructs.
In vitro analysis of osteogenic differentiation
Three groups of constructs with a volume of 600 ml were
bioprinted (alginate 3% and 107 cells/ml in medium): 1. Control
with empty GMPs (PBS laden), 2. Fast release with empty GMPs
(PBS laden) and 25 ng/ml BMP-2 in the alginate, 3. Slow release
with 25 ng/ml BMP-2 loaded on 2 mg GMPs. BCP granules were
omitted from these constructs to allow cell retrieval for FACS
analysis (Table 1). Constructs (n = 3) were cultured for three weeks
in expansion medium in a humidified incubator at 37uC and 5%
CO2. Part of the constructs was paraffin-embedded for histological
evaluation, the rest immersed in citrate buffer (150 mM NaCl,
55 mM sodium citrate and 20 mM EDTA in H2O) for 15 minutes
at 37uC to dissolve the alginate. The cell pellet was washed in
PBS/BSA 5% (w/v) three times and stained for flow cytometry.
This process was repeated with the gMSCs of three different
donors.
ALP analysis by FACS staining
Retrieved cells of each group (n = 3) were incubated with the
monoclonal anti-human alkaline phosphatase (ALP) conjugated
with Alexa fluor 647 (clone B4-78, BD Pharmingen, NJ, USA)
diluted 1:100 in PBS/1 % (v/v) FCS (Cambrex) in the dark for an
hour at 4uC. Control stainings were performed using isotype-
matched control antibody (IgG1). After antibody incubation cells
were washed and taken up in PBS/FCS and analyzed by FACS
Calibur.
Data were analyzed using a one-way ANOVA with Bonferroni
correction and expressed as mean6SD. A value of p,0.05 was
considered statistically significant.
Bioprinted constructs for in vivo analysis of osteogenic
differentiation
Three groups of constructs (Table 1) with a volume of 600 ml
were bioprinted (2062063 mm, alginate 3% and 107 cells/ml in
medium) as follows: 1. Control with empty GMPs (PBS laden), 2.
Fast release with empty GMPs (PBS laden) and 250 ng/ml BMP-2
in the alginate, 3. Slow release with 250 ng/ml BMP-2 loaded on
2 mg GMPs. Constructs were trimmed to a size of 106563 mm
and kept in expansion medium overnight before implantation.
BCP cylinders for bone formation analysis
Biphasic calcium phosphate cylinders (BCP-1150 containing 82
% HA and 18 %TCP, Xpand, Bilhoven, the Netherlands) 7 mm
in diameter, 3 mm in height with a porosity of 7561 % were filled
with 100 ml Matrigel, supplemented as follows (Table 1): 1.
Control with empty GMPs (PBS laden), 2. Fast release with empty
GMPs (PBS laden) and 100 mg/ml BMP-2 in 100 ml Matrigel, 3.
Slow release with 100 mg/ml BMP-2 loaded on 1 mg GMPs in
100 ml Matrigel.
Ethics Statement
This study was carried out following the Institutional Guidelines
under the Dutch Law (‘‘Wet op de dierproeven’’) on the use of
laboratory animals, in accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The study protocol was approved by
the Dutch Ethical Committee for Animal Experimentation (Dier
Experimentele Commissie, DEC) of the University of Utrecht, the
Netherlands (Permit Number: 06/248). All surgery was performed
under isoflurane anesthesia, and all efforts were made to minimize
suffering.
In vivo implantation
Six female nude mice (Hsd-cbp NMRI-nu, Harlan, Boxmeer,
The Netherlands), 6 weeks of age and 10 male Wistar rats (Charles
River), 16 weeks of age were housed in standard cages at the
Central Laboratory Animal Institute. They were allowed to
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acclimatize at the institute for at least two weeks prior to surgery.
Surgery was performed under inhalation anesthesia of 3 %
isoflurane. After skin incision subcutaneous pockets were made by
blunt dissection. The 3D printed scaffolds were placed in one of
the four dorsal pockets in the mice. The BCP cylinders were
placed subcutaneously in one of the six dorsal pockets in the rats.
All scaffolds were assigned to a subcutaneous pocket by
randomization. Pockets were closed using sutures (Vicryl 4.0).
Postoperatively the animals were weighed and given a subcuta-
neous injection of buprenorphin (0.05 mg/kg, Temgesic, Scher-
ing-Plough/Merck, Whitehouse station, NJ, USA) every 8 hours (3
times in total).
Sample processing
The mice were terminated by cervical dislocation 6 weeks after
implantation. The scaffolds were retrieved to analyze osteogenic
differentiation. Samples were fixed overnight in 4% buffered
formalin supplemented with 100 mM CaCl2 and further dehy-
drated for paraffin embedding. The rats were terminated with an
injection of Euthanasol. Scaffolds were retrieved and scanned with
micro-CT. Subsequently they were fixed in 4% buffered formalin,
dehydrated using ethanol series and embedded in polymethyl-
methacrylate (MMA).
Histology
Hematoxylin/eosin (HE) staining was performed on all paraffin
embedded samples to investigate the properties of the 3D printed
scaffolds directly after printing, after in vitro culturing for 3 weeks
and after 6 weeks of in vivo implantation.
Safranin O staining was performed to investigate GMP
distribution throughout the scaffold directly after printing and to
monitor alginate degradation after in vivo implantation. Sections
Figure 1. Bioprinted gelatin microparticles. A. Gelatin microparticles; B. GMPs in alginate, directly after printing, GMPs in pink; C. Section of
bioprinted alginate construct, directly after printing (H/E staining). Arrows indicate GMPs; D. Safranin O staining of bioprinted alginate construct,
directly after printing. Arrows indicate GMPs; E. Section of bioprinted alginate construct containing BCP, after 3 weeks of culturing (H/E staining).
Experiments were performed in triplicate, representative pictures are shown. Scale bars indicate in A: 200 mm, B: 2 mm, C,E: 500 mm, D: 100 mm.
doi:10.1371/journal.pone.0072610.g001
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were incubated for 5 minutes with Weigert’s hematoxylin after
deparaffinisation, washed for 5 minutes in running tap water,
rinsed in distilled water and counterstained with 5.2 mM Fast
Green solution. Sections were then rapidly rinsed 3 times in
166.5 mM acetic acid (Merck) and counterstained again with a
freshly prepared 3.56 mM Safranin O staining (Merck). Both
cultured and mouse implanted samples were immunostained for
osteocalcin, a marker for osteogenic differentiation. The cultured
samples were incubated with a mouse-anti-osteocalcin primary
antibody (TaKaRa M044, clone OCG4) at 40 mg/ml and a goat-
anti-mouse-IgG-HRP (Dako P0447) secondary antibody at 5 mg/
ml. The implanted samples were incubated with rabbit-anti-
osteocalcin primary antibody (Enzo ALX-210-333-C100) at 4 mg/
ml and a goat-anti-rabbit IgG-HRP (Dako P0448) secondary
antibody at 3.3 mg/ml. All antibodies were diluted in TBS
containing 5% BSA and 100 mM CaCl2, wash buffer consisted
of TBS supplemented with 0.1% (v/v) Tween20 (TBST). Stainings
were developed with diaminobenzidine (DAB) and Mayer’s
hematoxylin was used for counterstaining.
Sections of the bioprinted in vivo samples were deparaffinised
and incubated with Weigert’s hematoxylin, followed by Goldner’s
trichrome to assess collagen deposition. The MMA embedded
samples were sawed centrally into 25 mm thick sections using a
sawing microtome (Leica, Nussloch, Germany) and were stained
with methylene blue and basic fuchsin for histomorphometric
analysis. High-resolution digital pictures of the samples were taken
using transmitted light microscopy (Olympus-BX50, Olympus,
Zoeterwoude, the Netherlands). Bone and scaffold were pseudo-
colored red and green using Adobe Photoshop CS5.1 and
respective surfaces were measured (Adobe Systems Inc, San Jose,
USA). Bone area percentage was calculated as (bone area/(total
area - BCP area)*100%.
Micro-CT evaluation
Immediately after explantation of the subcutaneously implanted
BCP scaffolds, ex vivo micro-CT scans were acquired using a 9 mm-
resolution protocol (65 kV, 1320 ms exposure time, 1.0 mm Al
filter, 0.32 degree rotation step, 53 min scan). All micro-CT
images were reconstructed using volumetric reconstruction soft-
ware NRecon version 1.5 (Bruker micro-CT). The BCP scaffold
material was excluded through segmentation of the greyscale
images with a global threshold. Within the remaining pore space, a
second global threshold was applied to segment out calcified tissue
from non-calcified tissue and noise. Subsequently bone was
measured after an extra erosion step was applied to reduce border
artifacts caused by the BCP scaffold. All analysis and segmentation
was performed by a blinded observer.
Statistics
Histomorphometry data were analyzed by SPSS version 20
software (IBM, Chicago, Illinois, USA). Differences between
groups were analyzed with a paired t-Test. Post hoc testing was
performed using a Bonferroni correction. Significance was
assumed when p,0.05.
Results
Gelatin microparticles
Particles were uniform in shape when analyzed using light
microscopy (Figure 1A). GMPs were selected in the size range
between 75–125 mm out of three size ranges (0–50 mm/50–
75 mm/75–125 mm) since preliminary tests revealed that BMP-2
release from these spheres lasted up to three weeks (data not
shown). Smaller particles exhibited a faster growth factor release,
whereas release from larger particles was not tested since they
could hinder 3D printing with smaller gauged syringes [30].
In vitro release of BMP-2
To investigate whether GMPs could prolong release of BMP-2,
several release experiments were performed. After overnight
diffusional loading of BMP-2 solution, the amount of BMP-2 that
was present in the release medium was measured at multiple time
points up to 28 days. In figure 2A the cumulative release profile of
loading the microspheres with an 125I-BMP-2 solution in PBS with
collagenase A is shown, based on 125I signal in the medium. The
reproducibility of the experiment was very high, standard
deviations are less than 3 % and thus hardly visible in the figure.
In figure 2B the release of BMP-2 into PBS without collagenase
presence is shown, as measured with ELISA. An initial burst
release of about 20–30% of the BMP-2 was observed during the
first day, which was followed by a more sustained release for the
following four weeks. Without collagenase (Fig. 2B), the initial
burst of around 10 % occurred in the first day, followed by a slow
release until day 10 whereafter the growth factor was not further
released from the microspheres.
Bioprinting of controlled release particles
The GMPs were embedded in the alginate hydrogel and 3D
printed scaffolds were produced. Upon preparation of the 3D
printed scaffolds, GMPs were evenly distributed throughout the
Figure 2. Cumulative release profiles of BMP-2 from gelatin microspheres. A. Detection of 125I-BMP-2 in PBS supplemented with
collagenase, performed in triplicate. Results are presented as mean6SD (small SDs hardly visible in figure); B. BMP-2 concentrations in PBS without
collagenase, as determined by ELISA.
doi:10.1371/journal.pone.0072610.g002
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construct (Figure 1B). Constructs remained intact for at least three
weeks in vitro. Subsequently, we printed porous constructs
containing GMPs (without BMP-2/fast release/slow release) and
gMSCs from 3 different donor goats. One construct from each
donor and group was embedded into paraffin directly after
printing and stained with HE for gross histological evaluation. We
observed that scaffold architecture was well preserved. Note the
crossing of two hydrogel strands in the center of the picture
(Figure 1C). Two GMPs are in focus (arrows), others were lost
during tissue processing and left holes in the material. Staining
with Safranin-O was performed to further distinguish the alginate
(red) from the gelatin (green) and confirm distribution of the GMPs
throughout the scaffold (Figure 1D). The alginate contains
regional density differences, presumably caused by uneven degree
of crosslinking. The addition of BCP to the constructs did not
influence scaffold integrity and the strands were successfully
printed and remained intact, shown by HE staining (Figure 1E).
Osteogenic differentiation in vitro
The constructs were analyzed for osteogenic differentiation after
three weeks of culturing in expansion medium, by both detection
of ALP expression using FACS and immunohistochemistry for
osteocalcin. After dissolving the scaffold in citrate buffer flow
cytometry was performed. The number of ALP positive cells was
determined for all three conditions, as shown in Figure 3. Low
signal of the isotype matched control antibody group confirms
specific binding of the antibody. In one of the donors the number
of ALP positive cells increased when BMP-2 was present for a
longer period of time, in two donors the number of ALP positive
cells decreased. A beneficial effect of prolonged protein presence
was not seen, as the differences between the experimental groups
are not statistically significant. In the immunohistochemical
staining for osteocalcin the isotype-matched control staining was
negative (Figure 4A). In the control constructs 5.264.1 % of the
cells stained osteocalcin positive. In the fast release group
10.769.1% of all cells were expressing osteocalcin. In the slow
release group osteogenic differentiation was seen in 19.9613.6 %
of the cells (Figure 4B). There was no significant difference
between the groups (p = 0.2). Arrows indicate positively stained
cells.
Figure 3. Bioactivity of released BMP-2. Frequency of ALP positive
MSCs after culturing for three weeks without BMP-2 (control), with BMP-
2 in the hydrogel (fast release), and with BMP-2 laden GMPs (slow
release), determined for 3 individual donors. Statistical analysis
performed on mean values per donor.
doi:10.1371/journal.pone.0072610.g003
Figure 4. Osteocalcin staining of bioprinted scaffolds after 3 weeks of culturing. A. Control staining (isotype-matched control antibody); B.
Osteocalcin positive cells from a scaffold with slow release of BMP-2. Arrows indicate some of the positively stained cells (brown). Scale bars represent
50 mm; C. Percentage of osteocalcin positive cells per region of interest, no statistically significant differences were found. Results are presented as
mean6SD.
doi:10.1371/journal.pone.0072610.g004
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Osteogenic differentiation in bioprinted scaffolds
After 6 weeks of in vivo implantation in mice the scaffolds were
explanted and examined using immunohistochemistry. The
alginate scaffolds were degraded to such an extent that scaffold
retrieval was challenging, some explants were too small to analyze
for osteogenic differentiation. Larger pieces of retrieved scaffolds
(all from the fast release group) were suitable for histological
analysis (Figure 5).
In the retrieved scaffolds GMPs and BCP particles were clearly
visible on the HE staining. In the Goldner’s trichrome staining
collagen depositions (in green) were observed. Cells positive for
osteocalcin were present in the regions around both BCP and
GMPs, which indicates osteogenic differentiation at these
locations. No alginate was present in these tissues, as indicated
by staining with Safranin-O (data not shown). This indicates that
the loss of scaffold integrity occurred rapidly. To further
investigate this fast alginate degradation, two alginate/BCP
scaffolds were implanted subcutaneously in mice, and already
after one week alginate degradation and cell invasion was evident
(data not shown).
Bone formation in porous BCP cylinders
To analyze whether BMP-2 release kinetics influenced the
extent of bone formation, a second animal study was performed in
rats. Porous BCP cylinders (control, fast or slow release) were
implanted subcutaneously to ensure scaffold integrity throughout
the experiment. Bone formation in BCP cylinders was analyzed
using histomorphometry and micro-CT after 12 weeks of
subcutaneous implantation (Figure 6). The control group did not
form bone (060 %) in the BCP cylinders, which was significantly
lower than the BMP-2 containing groups (p,0.01, in both
histomorphometry and micro-CT). A bone volume of
5.560.9 mm3 was measured in this group with micro-CT. In
the slow release group a bone area of 13.568.3 % from the
histological sections and bone volume of 10.164.2 mm3 from the
CT data were measured. In the fast release group the average
bone area% reached 19610.7 %, and the bone volume
12.163.7 mm3.
Discussion
This study has shown that prolonged presence of BMP-2 in
scaffolds can be accomplished by applying controlled delivery
microparticles, such as GMPs. It is feasible to incorporate these
GMPs into a bioprinted alginate construct containing BCP and
gMSCs. The presence of BMP-2 in bioprinted hydrogel constructs
has led to osteogenic differentiation in vitro and in vivo. The ability
to place and release growth factors in such a way is novel and
offers many possibilities in terms of scaffold architecture and
bioactivity.
The 3% pre-crosslinked alginate was printable and could be
rapidly crosslinked after printing, but in vivo it was degraded very
fast, which severely affected scaffold integrity. The hydrogel with
incorporated BMP-2, BCP granules and gMSCs probably
dispersed through the pocket. The lack of coherence likely
explains the absence of bone formation after in vivo implantation,
as each of the components has been successfully used in bone
tissue engineering approaches in previous experiments by our
group [31,32]. The porosity of the constructs may have added to
the disintegration effect, as it enlarges the surface to volume ratio
of the constructs [33]. It is known that ionically cross-linked
alginate loses mechanical properties over time due to an outward
flux of ions into surrounding culture medium [34,35]. In the
future, other measures need to be taken to be able to make low
percentages of alginate printable, or combinations of hydrogels
should be used as scaffold material to retain structure until bone
starts to form.
Many different biomaterials are suitable for controlled release,
gelatin being well-known for its prolonged growth factor delivery,
characterized by a small initial burst and showing no tissue
damaging residual material. As such, gelatin is used in many FDA-
approved devices. The release profile of BMP-2 shown here has
two distinct phases, starting with a burst release of about 30%
growth factor. It is known from literature on gelatin release
kinetics that this burst is due to diffusion from the outer regions of
the particles [36]. The second phase, which shows sustained
release is suggested to be based on enzymatic degradation of the
gelatin, thereby releasing the bound BMP-2. When collagenase
was not present in the release medium this second phase hardly
occurred. Detection of the released protein was measured using
radioactive labeling as well as ELISA, both widely used assays to
assess BMP-2 concentrations. Still, these highly quantitative
methods do not take into account the loss of protein due to
breakdown and surface adhesion.
The in vitro release data shown in this article are probably not in
accordance with in vivo release rates, which can be significantly
faster due to higher enzymatic activities. By using collagenase in
the experiments, the in vivo degradation was at least partly
mimicked, but we expect in vivo release to be faster still. Also, a
100% release was not reached after 4 weeks, indicating there was
Figure 5. Osteogenic differentiation in vivo. Presence of gelatin
microparticles (GMP) and biphasic calcium phosphate granules (BCP)
after 6 weeks of subcutaneous implantation in mice as indicated in the
pictures. An overview and detail of HE, Goldner’s trichrome and
osteocalcin stainings are shown. Scale bars represent 100 mm.
doi:10.1371/journal.pone.0072610.g005
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still residual growth factor present in the experimental samples.
Give the observation that in vitro and in vivo release often show
different profiles [22], we can only estimate the total dose which
has become available in the implanted constructs. Dosage of BMP-
2 in the in vitro experiments appeared to be sufficient, as prolonged
presence of BMP-2 released from GMPs has led to osteogenic
differentiation of the cells.
In this study we used goat MSCs as a model system, because this
large animal model is widely used in preclinical studies aiming at
translation to the clinic and thus in generating cm-scaled bone
constructs. The presence of porosity in larger constructs promoted
tissue ingrowth and vascularization, which was demonstrated
before using the bioprinting technology [37]. When applying the
GMPs in bioprinted scaffolds, it appeared that inclusion of BMP-2
through these formulations containing growth factors is feasible.
Bone formation by application of BMP-2 laden GMPs was
studied, and results were analyzed using both histomorphometry
and micro-CT. Although micro-CT analysis poses advantages
such as rapid analysis of entire constructs and in vivo analysis, there
is a discrepancy with histomorphometry measurements, as is
illustrated by the control group. We know from histomorphometry
that no bone was present in these constructs, yet a considerable
signal was detected with micro-CT. This is presumably caused by
border-artefacts from the BCP, that has a radiolucency close to to
bone. Despite this over-estimation, the relative increase in bone
formation between the groups is comparable, which corresponds
to literature reporting good correlations between micro-CT and
histomorphometry [38]. Histomorphometry however remains the
gold standard to analyze bone formation. Growth factor induced
bone formation was analyzed, and growth factor presence either
Figure 6. Bone formation after 12 weeks of subcutaneous implantation in rats. A. Control group; B. Fast release of BMP-2 group; C.
Sustained BMP-2 released from GMP group. Section were stained with methylene blue and basic fuchsin. Biphasic calcium phosphate (BCP) is
indicated in the pictures. D. Quantification of bone content by histomorphometry, n = 10. E. 3D reconstruction of micro-CT showing bone formation
(orange) in a scaffold of the BMP-2 fast group. F. Quantification of bone content by micro-CT, n = 10. Representative pictures from each group are
given. Scale bars represent 100 mm in A-C, 1 mm in E; Results are presented as mean 6 SD, * p,0.01 compared to control.
doi:10.1371/journal.pone.0072610.g006
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by slow or fast release led to a significantly higher bone area %
compared to growth factor free formulations in the rat ectopic
model. This is in not in accordance with earlier studies in for
instance dogs, where the faster BMP-2 release led to higher ectopic
bone volume [39]. Apart from location specific differences, also
species differences play a role, making clinical translation even
more complicated.
Conclusion
We conclude from the current investigation that prolonged
BMP-2 release can be accomplished by loading the growth factor
on GMPs. The BMP-2 released from the GMPs in these scaffolds
is biologically active. Presence of BMP-2 in bioprinted hydrogel
constructs has led to osteogenic differentiation, from which we
conclude that it is feasible to bioprint a controlled release system.
BMP-2 significantly increased bone formation, the release timing
did not influence the bone volume within the constructs.
The ability to place and release growth factors in 3D printed
constructs is novel and offers many possibilities in terms of scaffold
architecture and bioactivity.
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